Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Between 1956 and 1981, 306 splenectomies for hematologic diseases were performed at the UCLA Medical Center. Of these operations, more than 75% were performed for therapeutic reasons to control anemia, thrombocytopenia, neutropenia, or painful symptoms of splenomegaly. Of the 65 patients who had idiopathic thrombocytopenic purpura, 77% showed an excellent response, and of the 39 patients who had hereditary spherocytosis, 90% responded. Other diseases with predictably good response rates were autoimmune hemolytic anemias, Felty's syndrome, and hairy cell leukemia. Forty patients with Hodgkin's disease had splenectomies for diagnostic purposes the last 10 years. The overall morbidity and mortality were 24% and 6%, respectively, the most common complications being pneumonia, wound infections, and local postoperative bleeding, and the most common cause of death being sepsis. The review supports the thesis that in carefully selected patients, therapeutic splenectomy can have desirable palliative effects and that diagnostic splenectomy has a sufficiently low risk to warrant its consideration in patients with Hodgkin's disease.
 ...
PMID:Splenectomy for hematologic disease. The UCLA experience with 306 patients. 673 25

Twenty-two patients with malignant lymphoma and its allied diseases, consisting of 6 with Hodgkin's disease, 10 with non-Hodgkin's's diffuse lymphoma, 4 with leukemic lymphosarcoma and 2 with immunoblastic lymphadenopathy, were entered into this study. The treatment schedule was intravenous drip infusion of the drug, at a dose of 2.3 to 5.4 mg/kg (150 mg to 300 mg/day), for consecutive 4 to 14 days. The total dose given ranged from 1050 to 2500 mg. Four of the 6 patients with Hodgkin's disease and 5 of the 10 patients with non-Hodgkin's diffuse lymphoma showed a good response. The response started from 3 to 7 days after beginning of BH-AC administration and remission induced by BH-AC persisted for 4 weeks. Clinical toxicities such as anorexia, nausea and vomiting were very mild, but hematological toxicities such as thrombocytopenia, leukopenia, and anemia were frequent especially in the patients who were totally given more than 2100 mg. This study suggested that malignant lymphoma responded definitely to single administration of BH-AC and that BH-AC might be a new useful drug for multi-combined chemotherapy of malignant lymphoma.
 ...
PMID:[Treatment of malignant lymphoma with single administration of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosylcytosine]. 676 8

Bilateral trephine bone marrow biopsies of 370 patients with Hodgkin's disease first seen at the Institute of Hematology, University of Rome, between 1970 and 1981, revealed tumor involvement of the bone marrow in 18 cases. The histologic type was mixed cellularity in 7 cases, lymphocytic depletion in 4 cases, nodular sclerosis in 4 cases, and lymphocytic prevalence in 1 case. Anemia with less than 10 g/dl of hemoglobin was observed in 5 patients; white blood cells were less than 4.0 X 10(9)/liter in 2 patients; platelets were less than 12.0 X 10(9)/liter in 1 case; a pancytopenic condition was observed in only 1 case. B symptoms were present in 14 of the 18 patients. All patients who underwent laparosplenectomy presented spleen involvement, 4 also had liver involvement. All patients were treated with chemotherapy; MOPP regimen was employed in 11 cases, ABVD in 5 patients, and PROVECIP in 1 case. Of the 13 patients evaluable for therapeutic response, 11 achieved complete remission, with a median actuarial relapse-free survival of 15 months. The actuarial survival curve showed that 50% of all patients are projected alive at 47 months with a follow-up ranging from 1 to 109 months.
 ...
PMID:Bone marrow involvement at onset of Hodgkin's disease. 683 48

Osler's influence in haematology was twofold: as an original observer both in the laboratory and the ward, and his encouragement of the establishment of clinical laboratories with the consequent development of clinical and laboratory haematologists. In 1870, when Osler entered McGill Medical School at the age of 21, he was already an experienced microscopist from his school days, but now his interest shifted from pond life to parasites and clinical microscopy. His post-graduate year with Burdon-Sanderson was to have been a study of leucocyte function, but instead came his research on platelets, continued and expanded when he returned to Montreal in 1874, together with much of his laboratory haematology--his comprehensive studies of pernicious anaemia and work on leukaemia, Hodgkin's disease etc. The move to Philadelphia in 1884 saw the establishment of a clinical laboratory, work on malaria, arsenic in anaemia and the blood disease chapter for Pepper's System. At Baltimore he had a rewarding clinical microscopy department, distinct from Welch's Institute, and this is the period, continued at Oxford, of Osler's accounts of clinical syndromes--polycythaemia, telangiectasia, mastocytosis and 'splenic anaemia'.
 ...
PMID:Osler's influence on haematology. 703 26

Autoimmune hemolytic anemia (AIHA) is very rarely associated with neoplasia in childhood. However, we have observed AIHA in three children with Hodgkin's disease (HD) in the past 7 years. AIHA presented either prior to, simultaneously with, or years after the diagnosis of HD. Antibodies against erythrocytes were nonspecific. The relationship of AIHA to the activity of underlying HD was quite varied among these three patients. Surgery, radiation therapy, and chemotherapy all may alter the course of AIHA. Coombs' tests may continue to be persistently positive when anemia is absent. Currently, all three patients have no evidence of recurrence of HD, no anemia, negative Coombs' tests 5 years, 22 months, and 14 years 10 months after the initial diagnosis of HD. AIHA should be considered in a child with HD who develops anemia and HD should also be considered in the differential diagnosis in a child with chronic AIHA.
 ...
PMID:Autoimmune hemolytic anemia in childhood Hodgkin's disease. 711 95

When human marrow cells were cultured in a medium containing alpha-medium, methylcellulose, fetal calf serum, bovine serum albumin, erythropoietin, and leucocyte-conditioned medium, mixed colonies composed of erythrocytic cells and granulocytes were formed. The clonal nature of the mixed colonies was confirmed by the linear relationship between the numbers of cells plated and the number of colonies, and the absence or presence of Y-chromatin in the mixed colonies in a co-culture experiment with male and female cells. Using the methylcellulose cell culture techniques, the pluripotent hemopoietic precursors (CFUMIX) in marrow cells from 15 patients with aplastic anemia were assayed. In the control subjects of patients with iron-deficiency anemia, lymphoadenitis, reactive leucocytosis or Hodgkin's disease, 8 X 10(5) marrow cells in 4 dishes produced 12.7 +/- 6.9 (mean +/- SD) mixed colonies. On the other hand, 8 X 10(5) marrow cells from patients with aplastic anemia formed only 2.1 +/- 5.5 (mean +/- SD) mixed colonies. Furthermore, the marrow cells from 5 patients who were repeatedly receiving transfusions contained no CFUMIX which give rise to mixed colonies. The present results provided the first direct evidence that pancytopenia in most patients with aplastic anemia results from a reduced influx into the compartment of maturing hemopoietic cells from the compartment of pluripotent hemopoietic precursors.
 ...
PMID:Pluripotent hemopoietic precursors in vitro (CFUMIX) in aplastic anemia. 722 71

The term lymphogranulomatosis X (LgX) designates a clinicopathological entity of unknown etiology ("X"), which was first described by Forster and Moeschlin in 1954. LgX includes the "immunoblastic lymphadenopathy" of Lukes and to a large extent the "angioimmunoblastic lymphadenopathy" of Rappaport (except for the cases with active germinal centers), but in LgX there is another morphologic variant not mentioned either by Lukes or by Rappaport. To establish the morphologic diagnosis of LgX three typical changes of the affected lymph nodes are needed: effacement of the nodal architecture, absence of active germinal centers, and markedly increased proliferation of epithelioid venules. Cases with only partial effacement of nodal architecture, and especially with active germinal centers, were considered hyperimmune reactions (HR). This "hyperimmune reaction" may be an early stage of LgX: 4 of 39 cases showed later transformation into LgX. Based on cytologic aspects, five different variants of LgX are distinguished: immunoblastic predominance, plasma cell predominance, mixed cell type, epithelioid cell predominance and lymphocytic predominance. Case history and clinical picture of the five variants of LgX (172 patients) are reported and compared with HR (37 patients). In LgX the age peak is in the 7th decade; the youngest patient was 16 years old. HR are seen in children as well as in elderly people, the mean age being 49 years. In LgX males predominate and in HR females. In LgX the disorder is usually more generalized than in HR (80% versus 46% with generalized lymph node enlargement, 69% versus 24% with hepatomegaly and 62% versus 27% with splenomegaly). Skin involvement and high sedimentation rate are less frequent in HR. In LgX a Coombs-positive anemia is occasionally found; its origin is "aplastic" rather than hemolytic. Based on the data presented, some reflections relative to the etiology and pathogenesis of LgX are presented. Rubella virus should be considered a possible etiologic agent. In most cases with drug hypersensitivity, allergic reactions to drugs appear only in the course of the illness; in these cases drugs are ruled out as an etiologic factor. Occasionally, an augmented number of azurophil granulated lymphocytes (suppressor T-cells?) is observed in the blood, a fact that could be a pointer to the pathogenesis of LgX and possibly explain the high incidence of infections seen in this disorder.
 ...
PMID:[History and clinical picture of lymphogranulomatosis X (including (angio)immunoblastic lymphadenopathy]. 726 65

The deformability of erythrocytes, which is a factor of utmost importance both for capillary perfusion and for determining erythrocyte life span, has been studied in patients with solid tumours and in healthy subjects. Deformability was significantly decreased in all patients, especially those with anaemia. In this latter group of patients, carboxyhaemoglobin saturation of blood (COHb), reflecting erythrocyte haemoglobin breakdown, was also significantly increased, and this increase was closely correlated with the degree of impaired deformability of the erythrocytes. In the group of patients without anaemia, where erythrocyte deformability was also impaired, no such correlation was found. In 4 patients with Hodgkin's disease and fever as part of B symptoms, erythrocyte deformability decreased during fever and returned to normal when fever subsided. In 2 of these patients the administration of a prostaglandin-synthesis inhibitor (indomethacin) evoked a deformability, which was even better than during periods without fever. Since fever in Hodgkin patients with B symptoms has been attributed to the production of prostaglandins, these results may suggest a relationship between prostaglandin production and erythrocyte deformability in patients with malignant tumours. The close correlation between the degree of decrease in erythrocyte deformability and COHb levels in the patients with anaemia might indicate a role for prostaglandins in the production of anaemia of malignancy.
 ...
PMID:Anaemia in patients with solid tumours and the role of erythrocyte deformability. 728 39

The records of 560 patients treated between 1972 and 1979 were reviewed. Nine patients had both autoimmune haemolytic anemia (AIHA) and Hodgkin's disease; 3 of them belonged to a group of 176 patients in whom a Coomb's test had been systematically performed. The incidence of the association was 1.7%. Five out of 9 patients were in clinical stages III or IV, and 8 had "B" symptoms. All patients were treated with 3 to 6 courses of MOPP followed by irradiation. The survival rate was 56.5% at 89 months. Three patients died, none of AIHA. The discovery of an AIHA at the time of diagnosis or during the course of Hodgkin's disease, the frequent finding of an excess of plasmocytes in Hodgkin's tumours and the negativation of Coomb's test by irradiation of these tumours suggest that the anti-erythrocyte activity originates in the tumoral tissue.
 ...
PMID:[Autoimmune haemolytic anaemia associated with Hodgkin's disease. Characteristics, prognosis and incidence (author's transl)]. 729 Sep 49

Fifty-five patients with celiac disease and coexistent malignant disease (27 lymphoma, 28 other malignancies) are described. The important clinical features at presentation of lymphoma were weight loss, abdominal pain, diarrhea, profound weakness and fever, associated with anemia, raised ESR, hypoalbuminemia and steatorrhea. There were no specific features to enable earlier diagnosis. Radiology was unhelpful and in no case were malignant cells seen in the jejunal biopsy. Four of the lymphomas were Hodgkin's disease, none of which involved the bowel; the remainder were reticulum cell sarcoma, 17 of which involved the bowel. Definitive diagnosis prior to death was made in only 18 patients, of whom 16 survived from 2 to 226 days (mean, 76 days). Of the remaining two patients, one is still alive, while the other died 26 years after the original diagnosis of Hodgkin's disease. The possibility of lymphoma should be considered in those who present with celiac disease in middle life and in those who deteriorate for no apparent reason after a period of stability on a gluten-free diet. The index of suspicion for lymphoma in celiac disease should be high and early laparotomy be considered in patients with unexplained deterioration. Twenty-eight patients with 29 carcinomas and 3 other tumors are also described. The presentations of these malignancies were no different from their presentations in non-celiac patients, and their development did not provoke a relapse of celiac disease. Considering the whole series of 55 patients, there was little evidence for the view that malignancy itself was the cause of the flat jejunal mucosal appearances seen in these patients.
 ...
PMID:Celiac disease and malignancy. 739 45


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>